Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication

Journal of Hypertension

Volumn 29, Issue 2, 2011, Pages 357-363

  Yoshida, Chikako ^a   Goda, Akiko ^a   Naito, Yoshiro ^a   Nakaboh, Ayumi ^a   Matsumoto, Mika ^a   Otsuka, Misato ^a   Ohyanagi, Mitsumasa ^a   Hirotani, Shinichi ^a   Lee Kawabata, Masaaki ^a   Tsujino, Takeshi ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

aldosterone; aldosterone escape; angiotensin II receptor blockers; calcium channel blockers; LV mass index

Indexed keywords

ALDOSTERONE; AMLODIPINE; LOSARTAN;

ADULT; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 78651297483     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834103d4     Document Type: Article

References (38)

1. Levy D, Garrison R, Savage D, Kannel W, Castelli W. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322:1561-1566.
2. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
3. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol 2001; 38:1829-1835.
4. Koren M, Devereux R, Casale P, Savage D, Laragh J. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to ngiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-2997.
6. Schmieder R, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275:1507-1513.
7. Dahlö f B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5:95-110.
8. Dahlö f B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001; 14:174-182.
9. Martina B, Dieterle T, Weinbacher M, Battegay E. Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology 1999; 92:110-114.
10. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43:2116-2123.
11. Fagard R, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54:1084-1091.
12. Weber K, Brilla C. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849-1865.
13. Neumann S, Huse K, Semrau R, Diegeler A, Gebhardt R, Buniatian G, Scholz G. Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002; 39:756-760.
14. Soylu A, Temizhan A, Duzenli M, Sokmen G, Koylu O, Telli H. The influence of aldosterone on the development of left ventricular geometry and hypertrophy in patients with essential hypertension. Jpn Heart J 2004; 45:807-821.
15. Daimon M, Watanabe H, Abe Y, Hirata K, Hozumi T, Ishii K, et al. Normal values of echocardiographic parameters in relation to age in a healthy Japanese population: the JAMP study. Circ J 2008; 72:1859-1866.
16. de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI study. Hypertension 2002; 40:470-476.
17. de Simone G, Palmieri V, Koren MJ, Mensah GA, Roman MJ, Devereux RB. Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens 2001; 19:119-125.
18. Lavie C, Ventura H, Messerli F. Regression of increased left ventricular mass by antihypertensives. Drugs 1991; 42:945-961.
19. Hammond I, Devereux R, Alderman M, Laragh J. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults. J Am Coll Cardiol 1988; 12:996-1004.
20. Lavie C, Schmieder R, Messerli F. Ambulatory blood pressure monitoring: practical considerations. Am Heart J 1988; 116:1146-1151.
21. Schmieder R, Lavie C, Messerli F. Diagnostic information provided by ambulatory blood pressure monitoring. Prog Clin Biol Res 1987; 227B:135-143.
22. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Shono M, Suzuki S, et al. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology 2006; 147:1314-1321.
23. Funck R, Wilke A, Rupp H, Brilla C. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997; 432:35-44.
24. Bauwens F, Duprez D, De Buyzere M, De Backer T, Kaufman J, Van Hoecke J, et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1991; 68:925-929.
25. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41:64-68.
26. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29:13-21.
27. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982; 49:1561-1563.
28. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7:1041-1044.
29. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40:28-33.
30. McKelvie R, Yusuf S, Pericak D, Avezum A, Burns R, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 1999; 100:1056-1064.
31. Horita Y, Taura K, Taguchi T, Furusu A, Kohno S. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin a nephropathy. Nephrology (Carlton) 2006; 11:462-466.
32. Sohn D, Chai I, Lee D, Kim H, Kim H, Oh B, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30:474-480.
33. Terpstra W, May J, Smit A, de Graeff P, Havinga T, van den Veur E, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: The ELVERA trial. J Hypertens 2001; 19:303-309.
34. Nishimura R, Schwartz R, Holmes DJ, Tajik A. Failure of calcium channel blockers to improve ventricular relaxation in humans. J Am Coll Cardiol 1993; 21:182-188.
35. Nagano R, Masuyama T, Naka M, Hori M, Kamada T. Contribution of atrial reservoir function to ventricular filling in hypertensive patients. Effects of nifedipine administration. Hypertension 1995; 26:815-819.
36. Brilla C, Funck R, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102:1388-1393.
37. Dez J, Querejeta R, Ló pez B, Gonzá lez A, Larman M, Mart?́nez Ubago J. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105:2512-2517.
38. Mottram P, Haluska B, Leano R, Cowley D, Stowasser M, Marwick T. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110:558-565.